The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Vitamin D supplementation for early-stage CLL is associated with prolonged TTFT and TFI
Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, presents a study examining the impact of vitamin D supplementation on patients with chronic lymphocytic leukemia (CLL) who are not currently undergoing treatment. The study reveals that vitamin D supplements extend both the time to first treatment (TTFT) and treatment-free interval (TFI), indicating a beneficial proactive strategy for untreated patients. However, confirmation of these findings awaits a prospective trial. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant or Consultations: Abbvie, Astra Zeneca, Roche, Janssen, Novartis, Takeda, Sanofi.
